Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 1
2013 1
2015 1
2016 2
2017 1
2019 5
2020 2
2022 1
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Advances in Precision Oncology: Targeted Thorium-227 Conjugates As a New Modality in Targeted Alpha Therapy.
Hagemann UB, Wickstroem K, Hammer S, Bjerke RM, Zitzmann-Kolbe S, Ryan OB, Karlsson J, Scholz A, Hennekes H, Mumberg D, Cuthbertson AS. Hagemann UB, et al. Among authors: bjerke rm. Cancer Biother Radiopharm. 2020 Sep;35(7):497-510. doi: 10.1089/cbr.2020.3568. Epub 2020 Apr 7. Cancer Biother Radiopharm. 2020. PMID: 32255671 Free PMC article. Review.
An efficient chelator for complexation of thorium-227.
Ramdahl T, Bonge-Hansen HT, Ryan OB, Larsen S, Herstad G, Sandberg M, Bjerke RM, Grant D, Brevik EM, Cuthbertson AS. Ramdahl T, et al. Among authors: bjerke rm. Bioorg Med Chem Lett. 2016 Sep 1;26(17):4318-21. doi: 10.1016/j.bmcl.2016.07.034. Epub 2016 Jul 17. Bioorg Med Chem Lett. 2016. PMID: 27476138 Free article.
A Targeted Thorium-227 Conjugate Demonstrates Efficacy in Preclinical Models of Acquired Drug Resistance and Combination Potential with Chemotherapeutics and Antiangiogenic Therapies.
Zitzmann-Kolbe S, Kristian A, Zopf D, Kamfenkel C, Politz O, Ellingsen C, Hilbig J, Juul MU, Fonslet J, Nielsen CH, Schatz CA, Bjerke RM, Cuthbertson AS, Mumberg D, Hagemann UB. Zitzmann-Kolbe S, et al. Among authors: bjerke rm. Mol Cancer Ther. 2023 Sep 5;22(9):1073-1086. doi: 10.1158/1535-7163.MCT-22-0808. Mol Cancer Ther. 2023. PMID: 37365121 Free PMC article.
Tumor growth inhibition and immune system activation following treatment with thorium-227 conjugates and PD-1 check-point inhibition in the MC-38 murine model.
Berg-Larsen A, Mobergslien A, Moen I, Petros G, Kristian A, Gunvaldsen KS, Cruciani V, Wickstroem K, Bjerke RM, Karlsson J, Cuthbertson A. Berg-Larsen A, et al. Front Med (Lausanne). 2022 Nov 15;9:1033303. doi: 10.3389/fmed.2022.1033303. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36457578 Free PMC article.
Preclinical Combination Studies of an FGFR2 Targeted Thorium-227 Conjugate and the ATR Inhibitor BAY 1895344.
Wickstroem K, Hagemann UB, Kristian A, Ellingsen C, Sommer A, Ellinger-Ziegelbauer H, Wirnitzer U, Hagelin EM, Larsen A, Smeets R, Bjerke RM, Karlsson J, Ryan OB, Wengner AM, Linden L, Mumberg D, Cuthbertson AS. Wickstroem K, et al. Among authors: bjerke rm. Int J Radiat Oncol Biol Phys. 2019 Oct 1;105(2):410-422. doi: 10.1016/j.ijrobp.2019.06.2508. Epub 2019 Jun 27. Int J Radiat Oncol Biol Phys. 2019. PMID: 31255687
Preclinical efficacy of a PSMA-targeted actinium-225 conjugate (225Ac-macropa-pelgifatamab) - a targeted alpha therapy for prostate cancer.
Schatz CA, Zitzmann-Kolbe S, Moen I, Klotz M, Nair S, Stargard S, Bjerke RM, Wickstrøm Biseth K, Feng YZ, Indrevoll B, Cruciani V, Karlsson J, Haendler B, Nielsen CH, Alfsen MZ, Hammer S, Hennekes H, Cuthbertson A, Hagemann UB, Larsen A. Schatz CA, et al. Among authors: bjerke rm. Clin Cancer Res. 2024 Apr 9. doi: 10.1158/1078-0432.CCR-23-3746. Online ahead of print. Clin Cancer Res. 2024. PMID: 38593212
Preclinical Efficacy of a PSMA-Targeted Thorium-227 Conjugate (PSMA-TTC), a Targeted Alpha Therapy for Prostate Cancer.
Hammer S, Hagemann UB, Zitzmann-Kolbe S, Larsen A, Ellingsen C, Geraudie S, Grant D, Indrevoll B, Smeets R, von Ahsen O, Kristian A, Lejeune P, Hennekes H, Karlsson J, Bjerke RM, Ryan OB, Cuthbertson AS, Mumberg D. Hammer S, et al. Among authors: bjerke rm. Clin Cancer Res. 2020 Apr 15;26(8):1985-1996. doi: 10.1158/1078-0432.CCR-19-2268. Epub 2019 Dec 12. Clin Cancer Res. 2020. PMID: 31831560
Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers.
Hagemann UB, Ellingsen C, Schuhmacher J, Kristian A, Mobergslien A, Cruciani V, Wickstroem K, Schatz CA, Kneip C, Golfier S, Smeets R, Uran S, Hennekes H, Karlsson J, Bjerke RM, Ryan OB, Mumberg D, Ziegelbauer K, Cuthbertson AS. Hagemann UB, et al. Among authors: bjerke rm. Clin Cancer Res. 2019 Aug 1;25(15):4723-4734. doi: 10.1158/1078-0432.CCR-18-3476. Epub 2019 May 7. Clin Cancer Res. 2019. PMID: 31064781
16 results